NFKB2 and prostate carcinoma: We believe that the small molecule inhibitor of the interaction of AR and p52 NF-κB subunit, AR/p52-02, represses the castration-resistant prostate cancer cell growth by blocking both AR and p52 pathways and may thereby prevent the transition of androgen-dependent growth of prostate cancer cells to castration-resistant growth.